🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Counseling + Transfer

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Addiction

    phase 3 small molecule completed

    1 trial

  2. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 small molecule terminated

    1 trial

  3. Cretostimogene Grenadenorepvec

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 3 mab active

    2 trials

  4. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  5. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  6. Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  7. Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  8. Crovalimab, Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  9. Crovalimab, ECULIZUMAB, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  10. Custirsen

    Teva Pharma GmbH

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  11. Cyclobenzaprine HCl

    Takeda

    Neck Pain

    phase 3 small molecule completed

    1 trial

  12. Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution

    The George Institute

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  13. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  14. Cytarabine

    The First People's Hospital of Lianyungang

    Leukemia

    phase 3 small molecule active

    1 trial

  15. Cytarabine

    Hoffmann-La Roche

    Leukemia, Myeloid, Acute

    phase 3 small molecule terminated

    1 trial

  16. Cytarabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 3 small molecule active

    3 trials

  17. DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  18. DACARBAZINE, PEMBROLIZUMAB, IDE196 (LXS196), CRIZOTINIB, IPILIMUMAB, NIVOLUMAB, CRIZOTINIB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  19. DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -

    Celgene Europe Limited

    Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis

    phase 3 small molecule active

    1 trial

  20. DAPAGLIFLOZIN, PLACEBO

    Disc Medicine

    Hypomagnesemia due to HNF1beta mutation

    phase 3 small molecule active

    1 trial

  21. DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg

    Pari Pharma GmbH

    Cardiac failure

    phase 3 small molecule active

    1 trial

  22. DAPAGLIFLOZIN, Placebo for dapagliflozin film-coated tablets 10 mg

    Disc Medicine

    Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population

    phase 3 small molecule active

    1 trial

  23. DAPAGLIFLOZIN, Zibotentan + Dapagliflozin, Zibotentan + Dapagliflozin

    AstraZeneca AB

    Chronic Kidney Disease and High Proteinuria

    phase 3 small molecule active

    1 trial

  24. DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, Etentamig, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources